| __timestamp | Neurocrine Biosciences, Inc. | Xenon Pharmaceuticals Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 17986000 | 5496000 |
| Thursday, January 1, 2015 | 32480000 | 9786000 |
| Friday, January 1, 2016 | 68081000 | 6792000 |
| Sunday, January 1, 2017 | 169906000 | 7313000 |
| Monday, January 1, 2018 | 248932000 | 8382000 |
| Tuesday, January 1, 2019 | 354100000 | 10803000 |
| Wednesday, January 1, 2020 | 433300000 | 12944000 |
| Friday, January 1, 2021 | 583300000 | 21967000 |
| Saturday, January 1, 2022 | 752700000 | 32810000 |
| Sunday, January 1, 2023 | 887600000 | 46542000 |
| Monday, January 1, 2024 | 1007200000 |
Unleashing insights
In the competitive landscape of biotechnology, effective cost management is crucial. Neurocrine Biosciences, Inc. and Xenon Pharmaceuticals Inc. offer a compelling study in contrasts over the past decade. From 2014 to 2023, Neurocrine's Selling, General, and Administrative (SG&A) expenses surged by nearly 4,800%, reflecting its aggressive growth strategy. In contrast, Xenon Pharmaceuticals saw a more modest increase of approximately 750% in the same period.
Neurocrine's SG&A expenses grew from a modest $18 million in 2014 to a staggering $888 million by 2023, indicating a robust expansion in operations and market presence. Meanwhile, Xenon's expenses rose from $5.5 million to $46.5 million, showcasing a steady yet cautious approach to scaling. This divergence highlights the varied strategies within the biotech sector, where companies balance innovation with financial prudence.
Breaking Down SG&A Expenses: AbbVie Inc. vs Neurocrine Biosciences, Inc.
Cost Management Insights: SG&A Expenses for Neurocrine Biosciences, Inc. and Viatris Inc.
SG&A Efficiency Analysis: Comparing Neurocrine Biosciences, Inc. and BioMarin Pharmaceutical Inc.
Operational Costs Compared: SG&A Analysis of Neurocrine Biosciences, Inc. and Jazz Pharmaceuticals plc
Cost Management Insights: SG&A Expenses for Neurocrine Biosciences, Inc. and Viking Therapeutics, Inc.
Cost Management Insights: SG&A Expenses for Neurocrine Biosciences, Inc. and Merus N.V.
Selling, General, and Administrative Costs: Neurocrine Biosciences, Inc. vs Ligand Pharmaceuticals Incorporated
SG&A Efficiency Analysis: Comparing Neurocrine Biosciences, Inc. and BioCryst Pharmaceuticals, Inc.
Ascendis Pharma A/S or Xenon Pharmaceuticals Inc.: Who Manages SG&A Costs Better?
Comparing SG&A Expenses: Pharming Group N.V. vs Xenon Pharmaceuticals Inc. Trends and Insights
ADMA Biologics, Inc. and Xenon Pharmaceuticals Inc.: SG&A Spending Patterns Compared